A 12-month, open-label, flexible-dosage study to evaluate the safety and efficacy of Gabitril treatment (up to 16 mg/day) in adults with generalized anxiety disorder [GAD]
Phase of Trial: Phase III
Latest Information Update: 07 Sep 2007
At a glance
- Drugs Tiagabine (Primary)
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- Sponsors Cephalon
- 07 Sep 2007 Status changed from in progress to completed.
- 05 Nov 2005 New trial record.